title: New approaches to the management of peripheral vertigo: efficacy and safety of two calcium antagonists in a 12-week, multinational, double-blind study.
abstract: OBJECTIVE
  To evaluate the efficacy and safety profile of one 30-mg nimodipine oral tablet taken three times per day (one tablet with breakfast, one with lunch, and one with dinner) or one 150-mg cinnarizine verum oral capsule taken once each day with dinner for 12 weeks.
  
  
  METHODS
  Comparative in a double-blind, multinational pilot study.
  
  
  METHODS
  Tertiary referral center.
  
  
  METHODS
  A total of 221 patients met the study criteria; of that total, 181 adult patients completed the study, including 135 women and 46 men whose ages ranged from 20 to 80 years.
  
  
  METHODS
  Two calcium antagonists were used to treat vertigo (nimodipine, 89 patients; cinnarizine, 92 patients), and all patients were maintained on the same dosage regimen until they completed 12 weeks of treatment. Patients were evaluated at 2-and 4-week intervals; an additional evaluation was made at Week 14 to determine vertigo recurrence in the posttreatment period.
  
  
  METHODS
  The response was evaluated by using the vertigo severity index, a count of vertigo episodes in a given time period. Each episode is weighted according to its intensity.
  
  
  RESULTS
  Nimodipine treatment decreased the incidence of moderate vertigo episodes by 78.8% and decreased severe vertigo episodes by 85.0%. Cinnarizine treatment decreased the incidence of moderate vertigo episodes by 65.8% and decreased severe vertigo episodes by 89.8%. Nimodipine and cinnarizine exhibited similar safety profiles. Only two patients withdrew from the study because of adverse events possibly related to the study drug. One patient withdrew from the cinnarizine group because of headache, and one patient withdrew from the nimodipine group because of lipothymia.
  
  
  CONCLUSIONS
  These data confirm the marked efficacy of both nimodipine and cinnarizine in the treatment of vestibular vertigo.
authors: Instituto Nacional de Neurología y Neurocirugía Dr. Manuel Velasco Suárez de la SSA, Av. Insurgentes Sur #3877, Col. La Famá, México 14269, D.F.
authors: Carlo Pane
authors: CP
authors: Pianese
authors: Lourdes Olivia Vales
authors: LO
authors: Hidalgo
authors: Ramón Hinojosa
authors: RH
authors: González
authors: Cecilia Esteinou
authors: CE
authors: Madrid
authors: Jorge Enrique Cruz
authors: JE
authors: Ponce
authors: Alberto Mañé
authors: AM
authors: Ramírez
authors: Luis Martínez
authors: LM
authors: Morán
authors: José Enrique Poó
authors: JE
authors: Arenas
authors: Arturo Torres y Gutiérrez
authors: AT
authors: Rubio
authors: Jorge Olguin
authors: JO
authors: Uribe
authors: José
authors: J
authors: Abiuso
authors: Enrique
authors: E
authors: Hanuch
authors: Juan
authors: J
authors: Alegría
authors: Claudio
authors: C
authors: Volpi
authors: Renate
authors: R
authors: Flaskamp
authors: Augusto Peñaranda
authors: AP
authors: Sanjuán
authors: Juan Manuel García
authors: JM
authors: Gómez
authors: Jaime
authors: J
authors: Hernández
authors: Alvaro
authors: A
authors: Pedraza
authors: Diana
authors: D
authors: Quijano
authors: Carolina
authors: C
authors: Martínez
authors: Juan Ramón
authors: JR
authors: Castañeda
authors: Oscar Jorge Cardeñosa
authors: OJ
authors: Guerra
authors: G Valencia
authors: GV
authors: F
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002121:Calcium Channel Blockers / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D002936:Cinnarizine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004584:Electronystagmography; D005260:Female; D006801:Humans; D007391:International Cooperation; D008297:Male; D008875:Middle Aged; D009553:Nimodipine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010865:Pilot Projects; D012008:Recurrence; D012720:Severity of Illness Index; D014717:Vertigo / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D002121:Calcium Channel Blockers; D002936:Cinnarizine; D009553:Nimodipine